HPGD

15-hydroxyprostaglandin dehydrogenase [NAD(+)] · P15428 · HPGD on Sugi Atlas →

3,660,425 patent compounds predicted against HPGD, 1,835,246 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4112	0.57	9/20
Pentachlorophenol (SCHEMBL1492)	1.00	8/20
SCHEMBL4015	0.73	8/20
Methacycline (SCHEMBL4014)	0.70	8/20
Methacycline (SCHEMBL4016)	0.70	8/20
Triclofenol (SCHEMBL1338)	1.00	7/20
Aspirin (SCHEMBL1353)	1.00	7/20
Aspirin (SCHEMBL7580)	1.00	7/20
SCHEMBL3446	0.62	7/20
SCHEMBL5459	0.61	7/20
Salicylic Acid (SCHEMBL3467)	0.59	7/20
Meclocycline (SCHEMBL3445)	0.59	7/20
Doxycycline Anhydrous (SCHEMBL3155)	0.50	7/20
SCHEMBL5237	0.50	7/20
SCHEMBL6935	0.50	7/20
Doxycycline Anhydrous (SCHEMBL3156)	0.49	7/20
SCHEMBL6666	0.46	7/20
Salicylic Acid (SCHEMBL1967)	1.00	6/20
Esculin (SCHEMBL2893)	1.00	6/20
Esculin (SCHEMBL2894)	1.00	6/20

Clinical trials — most relevant to HPGD by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
cindilizumab + Bevacizumab + Coenzyme I for Injection in Unresectable Hepatocellular Carcinoma	PHASE4	UNKNOWN
Efficacy and Safety of Oral Nicotinamide as an Adjunctive Therapy in Patients With Sepsis	PHASE4	NOT_YET_RECRUITING
European Celecoxib Trial in Primary Breast Cancer	PHASE3	COMPLETED
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes	PHASE3	UNKNOWN
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer	PHASE3	COMPLETED
Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors	PHASE1/PHASE2	COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
Comparision Between Paracetamol and Ibuprofen in Closure of Patent Ductus Arteriosus	PHASE2	UNKNOWN
Prostaglandin Inhibition for Emphysema	PHASE2	COMPLETED
Prostanoid Levels After Medication to Prevent Pain Following Third Molar (Wisdom Tooth) Extraction	PHASE2	COMPLETED
Vitamin E Supplements in Preventing Cancer in Patients at Risk of Prostate Cancer or Who Have Prostate Cancer	PHASE1	COMPLETED
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults	PHASE1	RECRUITING
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction	PHASE1	COMPLETED
A Dose Escalation Trial of Radiation Therapy (RT) for Hepatocellular Carcinoma (HCC)	PHASE1	UNKNOWN
Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients	nan	COMPLETED
Urinary PGE-MUM (PROSTAGLANDIN E-MAJOR URINARY METABOLITE) as Inflammatory Marker in Chronic Inflammatory Bowel Disease	nan	COMPLETED
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B	nan	COMPLETED
Mucomyst for Hepatitis C	nan	SUSPENDED
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A	nan	ACTIVE_NOT_RECRUITING
A Prospective Study to Evaluate the Effect of Chronic Nitrate Therapy on Vasodilation Function in Coronary Heart Disease	nan	UNKNOWN
Study About Patients Using Copper Intrauterine Device	nan	COMPLETED
Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates	nan	RECRUITING
Inflammation in COPD and the Effect of Nicotinamide Riboside	nan	COMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
Flow Mediated Dilation in Association With Hyperuricemia	nan	UNKNOWN
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
Forced Oscillometry in Infants With Bronchopulmonary Dysplasia	nan	RECRUITING
Effect of Supplementary Vitamins on Oxidant Gene Expression in the Lungs of Healthy Smokers	nan	COMPLETED
Association and Mechanism Between Cyclooxygenase-2 and Interleukin-6 in Gastric Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a HPGD binder may also engage these)

Protein	Name	Similarity
Q8MJY8	—	1.000	Q8MJY8 →
Q3T0C2	—	1.000	Q3T0C2 →
Q8VCC1	—	1.000	Q8VCC1 →
O08699	—	1.000	O08699 →
P70684	—	0.999	P70684 →
A0A8F5XX49	—	0.978	A0A8F5XX49 →
Q9ZUH5	—	0.977	Q9ZUH5 →
Q9M2E2	—	0.977	Q9M2E2 →
K4N0V2	—	0.977	K4N0V2 →
A3F5F0	—	0.976	A3F5F0 →
A0A3G9HAL8	—	0.976	A0A3G9HAL8 →
HSDL2	Hydroxysteroid dehydrogenase-like protein 2	0.976	landscape →
A0A165U5V5	—	0.975	A0A165U5V5 →
P0DKI3	—	0.975	P0DKI3 →
Q9WVK3	—	0.975	Q9WVK3 →
D2WKD9	—	0.975	D2WKD9 →
Q5RA68	—	0.974	Q5RA68 →
O08756	—	0.974	O08756 →
A4FUZ6	—	0.974	A4FUZ6 →
Q5RCF8	—	0.974	Q5RCF8 →
A0A6S6QNE4	—	0.973	A0A6S6QNE4 →
Q94KL7	—	0.973	Q94KL7 →
Q50L96	—	0.973	Q50L96 →
P22245	—	0.973	P22245 →
H9BFQ1	—	0.973	H9BFQ1 →
Q99LB2	—	0.972	Q99LB2 →
H9BFQ0	—	0.972	H9BFQ0 →
F4J2Z7	—	0.972	F4J2Z7 →
P27581	—	0.972	P27581 →
Q9C826	—	0.972	Q9C826 →